Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 13 of 13 for “"metastatic castration-resistant prostate cancer"”.
-
Chemoligand therapy for metastatic castration-resistant prostate cancer
<p>The disease of >70% of patients with metastatic castration-resistant prostate cancer (mCRPC) has moderate to high nonphysiological levels of a transmembrane protein known as prostate-specific membrane antigen (PSMA) and creates opportunities for precision medicine approaches. Using PSMA as a …
-
Characterizing glucocorticoid receptor in metastatic castration resistant prostate cancer
… and relevance in the context of enzalutamide resistant prostate cancer cells. Enzalutamide is a drug that functions to dampen androgen receptor (AR) signaling, thus inhibiting cancer dependency on the receptor protein. Although the application of the drug reduces AR signaling in these cancer …
-
Decoding the RNA cargo of plasma-derived extracellular vesicles in metastatic castration-resistant prostate cancer
… complement to tissue biopsies for monitoring cancer by capturing multiple molecular components circulating in body fluids, such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), cell-free RNA (cfRNA) and extracellular vesicles (EVs). EVs are nanoscale structures surrounded by a lipid …
-
Role of the extracellular matrix-integrin interaction in enzalutamide resistance of bone metastatic castration-resistant prostate cancer
Bone metastatic castration-resistant prostate cancer (bone mCRPC) is the most prevalent type of prostate cancer metastasis, accounting for 90% of all metastasis incidence. Its resistance to androgen-deprivation therapy (ADT). Enzalutamide (Enz) is a second-generation androgen-receptor (AR) …
-
The role of BET proteins in castration-resistant prostate cancer dissemination
The inevitable progression of advanced prostate cancer to castration resistance, and ultimately to lethal metastatic disease, depends on primary or acquired resistance to conventional androgen-deprivation therapy (ADT) and accumulated resistance mechanisms to evade androgen receptor (AR) …
-
Augmenting Natural Killer cell antibody binding to enhance ovarian and prostate tumor cell killing via ADCC
Ovarian cancer and metastatic castration resistant prostate cancer (mCRPC) are a leading cause of cancer-related deaths worldwide. Natural killer (NK) cells are cytotoxic lymphocytes that rapidly kill tumor cells via antibody-dependent cell-mediated cytotoxicity (ADCC). ADCC is exclusively mediated …
-
CRISPR/Cas9 screenings and in silico investigations nominate low-frequency alterations in DNA repair genes as biomarkers for castration-resistant prostate cancers.
… the treatment of multiple tumor types, including prostate cancer (PCa), and are associated with therapeutic response in metastatic castration-resistant prostate cancer (mCRPC) patients characterized by defects in homologous recombination repair genes. Clinical trials results suggest that further …
-
Targeting LEDGF/p75 to Sensitize Chemoresistant Prostate Cancer Cells to Taxanes
<p>Prostate cancer (PCa) is the second most diagnosed cancer in males. This disease disproportionately affects African American men, with a higher incidence and mortality compared to other ethnic/racial groups. An aging male population and the complexity of addressing the health disparities …
-
The DNA methylation landscape of metastatic prostate cancer: from characterization to liquid biopsy applications
… alterations are observed in virtually all cancer types, yet there is limited understanding of their role in tumorigenesis and evolution. The role of DNA methylation has been particularly elusive in this context. While this epigenetic mark has been extensively profiled in healthy and …
-
Functional characterization of mobilized tumor cells
Despite being responsible for 90% of cancer mortality, metastasis is not well understood. This thesis is focused on the circulation step of the metastatic cascade, examining three types of mobilized tumor cells: circulating tumor cells (CTCs), intraoperatively shed tumor cells, and malignant …
-
Targeting the Tumor Stroma Using a Monoclonal Antibody Platform Technology
1 in 9 men will be diagnosed with prostate cancer during their lifetime and it remains the second leading cause of cancer death among American men. Men who fail standard-of-care androgen deprivation therapy (ADT) and progress to metastatic castration resistant prostate cancer (mCRPC) are left with …
-
Regulation of Systemic and Cellular Metabolism In Prostate Cancer By Camkk2 and Elucidation of Atgl’S Role In Disease Progression
… androgen receptor (AR) is the major driver of prostate cancer; hence, men with progressing disease are treated with androgen deprivation therapy (ADT). However, the majority of patients will relapse within 2-3 years due to multiple AR reactivation mechanisms. Thus, AR and the processes …
-
Discovery of Inhibitors of Inhibitors of Apoptosis Proteins and Novel Tubulin Polymerization Inhibitors as Potential Anticancer Agents
<p>The global impact of cancer as a significant public health concern is undeniable. According to the annual report by the American Cancer Society, projections for 2023 estimate 1,958,310 new cancer cases and 609,820 cancer-related deaths in the US. Recent years have seen significant progress in …